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Abstract
Design of a novel isoxazoline class drug for the suppressive treatment of erythrocytic malaria
through the inhibition of Plasmodium Falciparum Gylceraldehyde-3-phosphate Dehydrogenase
(PfGAPDH) gave rise to creation of a synthetic plan for the proposed target molecule α-amino3-bromo-4,5-dihydroisoxazol-5-yl propionic acid. A literature-based analysis of the moieties
targeting the PfGADPH active site led to the design of the target molecule. Subsequently, an
exploration of the literature yielded a possible bifold synthetic plan. Attempts at a model
epoxidation reaction using mCPBA and further efforts towards the synthesis of a 3bromoisoxazoline were shown to be successful using GCMS analysis.
Introduction
Malaria is vector borne illness caused by protozoan parasites within the genus
Plasmodium. Plasmodium falciparum is one of the five malarial parasites known to infect
humans--P. falciparum, P. knowlesi, P. malariae, P. ovale, and P. vivax.1 As vector borne
parasites, all of the malarial causing Plasmodium, except for P. Knowlesi, use the female
Anopheles mosquitos as their vector and definitive host, where the sexual phase occurs, and
humans as the intermediate host, where the asexual phase occurs.2 The World Health
Organization (WHO) recognizes Plasmodium falciparum as the deadliest form of malaria. In
2015, the WHO reported malaria’s alarming morbidity rate of 407 cases per minute and a
mortality rate of 1 fatality per minute.1 The Centers for Disease Control state that, Malaria
commonly occurs in Africa, Central and South America, parts of the Caribbean, Asia, Eastern
Europe, and the South Pacific.3 Out of the five malaria parasites that infect humans, the World
Health Organization recognizes Plasmodium Falciparum as the deadliest and as the most
prevalent within the African Region. The WHO’s 2019 World Malarial Report confirms 228
million cases of malaria in 2018 with 405,000 deaths globally. Children under the age of 5
accounted for 67% of these deaths.4
Malaria holds significance in the history of the United States public health system.
Efforts for control and eradication of the disease prompted the creation of the Office of Malaria
Control in War Areas in 1942 which became the well-known public health and epidemiological
organization the Centers for Disease Control and Prevention (CDC) in 1946. The CDC notes that
although “malaria was considered eliminated” in 1952, less than five years after the formation
of the CDC, malaria remains both a national threat and global issue.5 “Approximately 2,000
cases of malaria are reported each year in the United States” paired with the continued
presence of Anopheles mosquitos in the United States, the potential for a malarial epidemic in
the United States persists.6 Continued efforts in containment, prevention, and eventual global
elimination require the significant attention and resources of major public health and nonprofit
organizations including the CDC and the WHO.5
The WHO’s designation of Plasmodium Falciparum as the deadliest form of malaria and
its increasing resistance to available treatments requires the design of new drugs. Because of
this, the goal of this research was twofold: to design a novel isoxazoline class drug for the
suppressive treatment of Plasmodium Falciparum and to create a potential synthetic plan for
the target drug.
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Design of Novel Isoxazoline Compound
Malaria is a vector borne disease, which means
that infectious parasites are transmitted from one
host to another. Plasmodium Falciparum uses the
female Anopheles mosquito as its vector and
definitive host, which is where the sexual phase
occurs, and humans as its intermediate host which is
where the asexual phase occurs. Once the infectious
parasites enter the human body, they infect the liver
and then the red blood cells. During the asexual blood
stage of P. falciparum, a single infected red blood cell
can release between “14 and 32 daughter merozoites”
every two days.7 Once released back into the blood
stream, these merozoites will infect new blood cells Figure 1 Life Cycle of Malaria from “Life Cycle of Malaria.”
and perpetuate the cycle of asexual reproduction.1
The asexual blood stage of malarial infection causes clinical symptoms such as “high
fevers, shaking, chills, and flu-like illness.”3 Because of this, Suppressive treatments, aim to
eliminate malaria symptoms by targeting parasites within red blood cells. During the blood stage,
both the infected red blood cells and the parasites rely on anaerobic metabolism to produce ATP.
As suggested by Kumar (2018), glycolytic enzymes such as glyceraldehyde-3-phosphate
dehydrogenase (PfGAPDH), have the potential to be great cytosolic drug targets, because
malarial parasites rely heavily on glycolysis for energy and glycolytic enzymes’ amino acid
sequences are often well conserved.8 Therefore, glycolytic enzymes are good drug targets for
suppressive treatments, because they do not easily form resistance and the parasites require
glycolysis to continue growth.
A key enzyme for erythrocytic stage of pf
malaria
is
Glyceraldehyde-3-phosphate
dehydrogenase. This enzyme catalyzes the
conversion of glyceraldehyde 3-phosphate into
1,3-bisphosphoglycerate (1,3-BPG) and uses a
cofactor of NAD+ and (inorganic phosphate) Pi. At
this point in glycolysis the parasite has already
invested 2 ATP. It is significant that PfGAPDH
shares only 65% of its identity with its Human
Figure 2 Reaction catalyzed by PfGAPDH
analog. Additionally, the insertion of the dipeptide
(lysine—glycine) in the S loop of the PfGAPDH
allows for selective inhibitory action by heme.9
In 2014, Bruno et al. first suggested the use of isooxazoline class drugs—such as acivin
and 3-bromo-acivin—to inhibit the catalytic cysteine of PfGAPDH. Early on in this project, a
generalized target molecule which adapted the isoxazoline scaffold from 3-bromoacivin was
proposed as seen in figure 3. This target molecule changed 3-bromo group on 3-bromoacivin to
an acetoxy group, because inhibitory activity caused by the nucleophilic attack of catalytic cystine
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Figure 3 Proposed
target molecule
11/5/2018

residues was greatly influenced by the leaving group in the 3 position on the
isoxazoline ring.10 Additionally, to further characterize the binding site of PfGAPDH,
the amino acid was protected in a heterocyclic ring. In Spring 2019, significant time
was invested towards the synthesis of this molecule. The first attempt to synthesize
our target molecule, reactions towards a model an aldoxime starting reagent, a
subsequent isoxazoline, and finally 1,1-dibromoformaldoxime. GCMS analysis proved
these reactions to be unsuccessful. Because of this, the literature was revisited, and
the target molecule was adapted. During the reassessment of the original target
molecule there was an emphasis on literature that discussed PfGAPDH’s natural
and synthetic inhibitors and its mechanisms. Once a new target molecule was
proposed, then potential synthetic routes were sought.

Compound
Structure

3-bromoacivin

3-bromoacivin derivative
heme

Reference(s)
Kinetic Data

11,12

Kitz-Wilson Kinact/Ki
Ratio=.7s-1M-1

3-bromo group on
Key Features isoxazoline core, 5-⍺amino-acetic acid moiety

Conclusions

Original lead compound, 3bromo group binds
irreversibly with Cys
residues (PfGADPH
catalytic Cys153), position
of the carboxylic acid Hbond donator reduces
effective inhibition
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8,9,13,14

Kitz-Wilson Kinact/Ki
Ratio=10.7s-1M-1

n/a

3-bromo group on isoxazoline
core, 5-⍺-amino-methyl
acetate moiety

Propionic acid groups on five
membered heterocyclic rings (3pyrroline and pyrrole, respectively)

Solidifies the use of the 3bromo group, most favorable
positioning of bromine leaving
group, Protonated amine Hbonds with Thr154 & Gly215,
Higher Kitz-Wilson Kinact/Ki
Ratio represents greater
inhibition potential

One of two propionic acid groups
inhibit PfGAPDH by positioning itself
within the NAD+ binding site and
both liganded and covalent thioether
linkages to Cys residues, the insertion
of –KG-- within the S loop leads to
the selective inhibition of PfGADPH
over human PfGAPDH

Table 1. Analysis of Literature Compounds

4

As previously stated, Bruno et al. (2014) first suggested the use of 3-bromoacivin to
inhibit the catalytic cysteine of PfGAPDH.12 In 2019, the same research group released a paper
further characterized the mechanism by which the 3-bromo-isoxazolines irreversibly reacted
with the catalytic Cys153 of PfGAPDH and how various moieties in the 5 position affected this
inhibitory action.11 This article confirmed that the 3-bromo group on the original lead
compound, 3-bromoacivin, binds irreversibly with the PfGADPH catalytic Cys153. However, it
was also found that the position of the carboxylic acid H-bond donator on the 5-group reduced
inhibition as demonstrated by the lower Kitz-Wilson ratio compared to the 3-bromoacivin
derivative with a much higher lower Kitz-Wilson ratio seen in table 1. The higher the Kitz-Wilson
ratio, the greater the inhibition. Therefore, the 3-bromoacivin derivative demonstrated the
greatest inhibition of PfGAPDH. The extended 5-group side chain by one carbon through the
use of a methoxy group may have allowed for the 3-bromoacivin derivative to have most
favorable positioning of bromine leaving group. Additionally, the protonated amine in the 3bromoacivin derivative H-bonded with Thr154 & Gly215. Figure 4 demonstrates mechanism of
inhibition of catalytic cysteine by acivin and other 3-haloisoxazolines the includes the direct
modification of the active site as the nucleophilic sulfur attacks carbon 3 on the isoxazoline ring
causing the chloride to leave.15 In 3-bromoacivin the 3-chloro leaving group would be a 3bromo group. It becomes apparent the position of an H-bond donor such as an amino acid
could interfere with the basic amino acid’s de-shielding of the catalytic cysteine. Because of
this, an elongated side chain for the 5-group was considered, and the amino group was found
to be potentially significant. Since Cullia et al. 2019 further established the success of the 3bromo group in reacting with catalytic cysteines, the idea of 3-acetoxy group from the previous
target molecule was rejected, and the use of the 3-bromo group as the leaving group on the
target molecule was established.

Figure 4. Mechanism of inhibition of catalytic cysteines by acivin and other 3-haloisoxazolines through the direct modification of the active site
(Kreuzer 2014).

The most prevalent suppressive treatments for malaria, such as hydroxychloroquine,
disrupt the asexual blood stage through the inhibition of parasite mechanisms which participate
in the “degradation and detoxification of host hemoglobin.”7 This is because erythrocytic
Plasmodium Falciparum degrade hemoglobin to heme. This free heme inhibits various
Plasmodium proteins, including PfGAPDH.13 Despite the parasite’s increased resistance to some
of these drugs, heme’s naturally toxic effects remain. As seen in table 1, one of the two propionic
acid moieties of heme inhibit PfGAPDH by positioning itself the within NAD+ binding site.14
Additionally, heme inhibits PfGAPDH through both liganded and covalent thioether linkages to
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Cys residues.13 PfGAPDH only shares 65% of its identity with its Human analog.1 The major
structural distinction of PfGAPDH of an “insertion of a dipeptide (-KG-) in the so-called S loop. .
.may be responsible for the selective inhibition of the enzyme [PfGAPDH] by heme.”9 This is
significant because it may explain why heme “shows little inhibition of RBC GAPDH,”
which could allow for targeted inhibition of PfGAPDH using the propionic acid heme
moiety as shown in the image.9 Therefore, a propionic acid moiety on the 5-group was
proposed for the target molecule.
After revisiting the literature, α-amino-3-bromo-4,5-dihydroisoxazol-5-yl
propionic acid was proposed as an ideal target molecule as seen in figure 5. The structure
includes a 3-bromo group on an isoxazoline core because this moiety has demonstrated
covalent inhibitory action with the catalytic cysteine (Cys153) within the active site of
PfGDAPDH. Additionally, the 5-propionic acid group was chosen because of the inhibitory
Figure 5 Target
action of propionic acid heme moieties. The small change of extending the carbon chain
Molecule αof the amino acid group by 1 carbon lead to the creation of a synthetic plan for the
amino-3-bromo4,5proposed target.
dihydroisoxazolSynthetic Plan for Target Molecule
5-yl propionic
One of the most unique reactions
acid
in the proposed synthetic plan is the
synthesis of an isoxazoline. While the 1,3-dipolar
cycloaddition reaction has been around for many
years, isoxazoline class molecules have received
recent attention for their possible bioactivity.
Namboothiri et al. 2008 states that “Isoxazolines
exhibit interesting and diverse biological
properties and represent a unique class of Figure 6 Mechanism of 1,3 dipolar cycloaddition
pharmacophores.” As nonaromatic heterocycles,
“Their therapeutic potential presents exciting possibilities”--Isoxazoline class molecules possess
“antimicrobial, anti-inflammatory, fibrinogen receptor antagonistic, anticancer, antiHIV, caspase
inhibitory, and antidepressant properties.”16 In 1963, Dr. Rolf Huisgen presented 1,3-dipolar
cycloaddition as a useful method for the “synthesis of five-membered heterocycles.”17 Using this
route, nitrile oxide, a zwitterionic 1,3-dipole, reacts with an alkene, a dipolarophile, to form
an ∆2 –Isoxazoline (4,5-dihydroisoxazole). Because of this a two-phase reaction synthetic route
has been suggested. Phase 1 focuses on the synthesis of an ideal dipolarophile modeled after the
synthesis of Garner’s Aldehyde, while phase 2 includes the 1,3-dipolar cycloaddition and
deprotection of an amino acid.
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Modeled after the
protection of a beta-amino
alcohol as seen in the
synthesis of Garner’s
Aldehyde, synthetic route
suggests an approach for
the synthesis of our target
molecule. The goal of the
first phase of the synthetic
Figure 8 Phase 1 of proposed synthetic route
plan as seen in is to
synthesize an alkene with a
tert-butyloxycarbonyl (boc)
N-protected beta-amino
alcohol as seen in figure 7.
This alkene would serve in
as a dipolarophile in the
1,3-dipolar cycloaddition
reaction. The first step in
the reaction is a
monoepoxidation of 1,4Figure 7 Phase 2 of proposed synthetic route
pentadiene, an
unconjugated, symmetric diene, resulting in 2-allyoxirane.18,19 Followed by a regioselective
aminolysis or ring opening of the epoxide yielding a beta-amino alcohol.20–23 Step 3 protects the
N-group of the beta-amino alcohol with a boc protecting group.24,25 Finally, step 4 protects the
N-protected beta-amino alcohol within a heterocycle and leaves the alkene available for the
1,3-dipolar cycloaddition reaction.24
Phase 2 of the proposed synthetic plan includes the formation of the
3-bromoisoxazoline and the deprotection and oxidation of the N-protected beta-amino alcohol
to an amino acid. The alkene which results from phase 1 of the synthetic plan will act as
dipolarophile and react with a nitrile oxide formed from 1,1-dibromoformaldoxime.12,26,27 Steps
6 and 7 remove the cyclized protection from the N-protected β-amino alcohol and oxidize the
alcohol to an acid.10,26 Finally, step 8 removes the boc-protecting group from the resulting
amino acid.26,28 This results in a molecule which fits the criteria for the inhibition of PfGAPDH
based on our literature-based analysis of the active site. The identification of this possible
synthetic route allowed for effective modeling of steps 1 and 5 as discussed below.
Discussion and Results
As this project progressed, multiple target compounds were proposed, and the
synthesis of multiple target compounds was attempted. Because of this, the experimental
sections will be separated into two sections—target molecule 11/5/18 and novel 3bromoisoxazoline—indicated by * and ** respectively.
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For the first attempt to
synthesize a model of the target
molecule 11/5/18, an aldoxime
was attempted to be synthesized
from isobutylformate using the
procedure for intermediates 1-3
from Rodrigues (2013). This
would result with a 3-isobutoxy
group on the isoxazoline ring as
seen in figure 9. Methods 1ab and
2ab were clearly unsuccessful.
After looking at the GCMS data
Figure 9. Reaction scheme for methods 1ab and 2ab as discussed in table 2.*
from project 2, products and
starting materials were unable to
be detected. This was strange because if the
reaction did not proceed properly then the
starting reagents should be present in the
solution. Isobutylformate may not be reacting
well to form the aldoxime and subsequently
the nitrile oxide. Because of this, we returned
to the literature discussing Garner’s
Aldehyde.26
Figure 10. 3-Bromo to 3-Ether Group Substitutions from Pinto (2008)
and Tamborini (2012).*
After a revisit to the literature, it
became apparent that many novel
isoxazolines could be created through the
substitution of a 3-bromo group for a 3ether group as seen in figure 10.26,27,29 The
first step in the synthesis of a 3-bromoisoxazoline required the synthesis of
dibromoformaldoxime from glyoxylic acid,
because 1,1-dibromoformaldoxime was
Figure 11. Methods 3 and 4: Synthesis of Glyoxylic Acid Aldoxime using
general aldoxime synthesis procedure from Ramòn (2010) to eventually
relatively expensive and glyoxylic was
form Dibromoformaldoxime as suggested by Wang (2017) abstract.*
available. Because of this, methods 3-6
were attempts to synthesize 1,1dibromoformaldoxime.
Since other researchers had found
success using the general procedure for the
formation of an aldoxime from Ramòn
(2010), the suggested procedure for the
aldehyde considered closest to glyoxylic
acid was used for Methods 3 and 5.30 While
Figure 12. Methods 4 & 6: Synthesis of Dibromoformaldoxime from Wang
adding NaOH to the reaction mixture, the
(2017) abstract.*
temperature spiked during method 3,
which could have affected the reaction.
8

However, because aldoximes have the potential to be relatively unstable, the synthesis of 1,1dibromoformaldoxime in method 4 was continued.
The procedure for Methods 4 and 6 was based off of a reaction scheme seen in the
Wang (2017) abstract as seen in figure 12 and discussed in table 5.31 Despite the improved
temperature control for method 6, both methods 4 and 6 proved to be unsuccessful as
confirmed by GCMS. The limited access to the established procedure for the formation of both
glyoxylic acid aldoxime and dibromoformaldoxime hindered us.
Synthesis of Aldoxime
Method
Reagents
Variations in Method
Product Description
GC-MS Analysis

Method 1a
Isobutyl Formate, Hydroxylamine
hydrochloride
Methanol as solvent

Method 2a
Isobutyl Formate, Hydroxylamine
hydrochloride
Ethanol as solvent

Clear colorless liquid
Presence of isobutyl formate starting
material at 3.451 min peak

Clear colorless liquid
Presence of isobutyl formate starting
material at 3.444 min peak

Table 2. Summary of synthetic methods attempted in the synthesis of an aldoxime from isobutylformate.*

Synthesis of Isoxazoline
Method
Method 1b
Product mixture produced using Method
1a, triethylamine, cyanuric acid trichloride,
Reagents
methyl acrylate
Variations in Method
Product Description
GC-MS Analysis
Percent Yield

Method 2b
Product mixture produced using
Method 1b, triethylamine, cyanuric
acid trichloride, methylacrylate

Diethyl ether as solvent

Dichloromethane as solvent

Yellow tinted clear liquid, some crystalized
solid
Peak at 2.267 min indiscates the presence
of unreacted methyl acrylate starting
material
------------------------

White goo with crystals
Confirmation of solvent diethyl ether
at 1.310 min peak
149.3% (1.39g)

Table 3. Summary of synthetic methods attempted in the synthesis of an isoxazoline from the products of method 1a and
method 2a, respectively .*
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Synthesis of Glyoxylic Acid
Aldoxime
Method
Method 3
glyoxylic acid monohydrate, hydroxylamine
hydrochloride, sodium hydroxide
Reagents

Variations in Method
Product Description
GC-MS Analysis
Percent Yield

Method 5
glyoxylic acid monohydrate,
hydroxylamine hydrochloride, sodium
hydroxide

More ice, temperature rose to 30oC, filtered Allowed aqueous NaOH to fully cool,
dried organic solution using scoops of
organic solution through MgSO4
MgSO4
Clear colorless liquid
Clear colorless liquid
Unclear spectrum
26.9% (.482g)

1.303 min peak --Propanoic acid in
the library search
59.3% (1.0565g)

Table 4. Summary of synthetic methods attempted in the synthesis of an aldoxime from glyoxylic acid aldoxime towards the
synthesis of 1,1-dibromoformaldoxime.*

Synthesis of 1,1Dibromoformaldoxime
Method
Reagents
Variations in Method
Product Description
GC-MS Analysis
Percent Yield

Method 4
Product mixture produced using Method 3,
liquid bromine
Adapt mol ratio to mol of product mixture
(.482g) from Method 5
Yellow, white, and peach colored solid

Method 6
Product mixture produced using
Method 5, liquid bromine
Adapt mol ratio to mol of product
mixture (1.0565g) from Method 5
Red/yellow clear liquid

Red solution--Confirmation of solvent at
Ethyl acetate peak is present at 2.267
peak 2.198 min; yellow solution-min
Confirmation of solvent at peak 2.216 min
6% (.074g)
-----------------------

Table 5. Summary of synthetic methods attempted in the synthesis of 1,1-dibromoformaldoxime from the products of method 3
and method 4, respectively .*

An epoxidation reaction is a textbook
reaction, and though there appears to be theoretical
support for the monoepoxidation of an unconjugated
diene, there was some uncertainty in the
methodology provided and whether the starting
Figure 13. Methods 7, 8, 12, and 13: Synthesis of a terminal
materials will behave in an ideal way.19 Because of
epoxide (1,2-epoxypentane) from pentene using the Prilezhaev
this, and the cost of the starting reagent 1,4reaction. Model reaction of step 1 of phase 1 of the proposed
pentadiene, step 1 of phase 1 was modeled. Two
synthetic plan.**
methods—12 and 13—for the synthesis of a terminal
epoxide from pentene using m-chloroperoxybenzoic acid as the epoxidizing agent proved
successful. For method 12, the epoxidation of pentene procedure was adapted from Porto (2005)
by adding pressure. For method 13, a biphasic epoxidation procedure using benzyl triethyl amine
chloride as phase transfer agent was attempted.32,33 Both were proved to be successful by GCMS
analysis.
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Methods 9ab and 11 hold significance as
potential model reactions for the synthesis of a
β-amino alcohol using the aminolysis of an
epoxide with ethyl carbamate. As seen in step 2
of phase 1 of the synthetic plan, β-amino
alcohols are biologically active compounds
which can be synthetic intermediates--as a
protected amino acid and unprotected then
oxidized to form an amino acid. Many β-amino
Figure 15. Reaction scheme from Method 9ab. Model reaction for
the combined steps 2 and 3 of phase 1 of the proposed synthetic
alcohols are used as “β-blockers, insecticidal
plan. Attempt to complete a pH catalyzed opening of 1,2agents, and chiral auxiliaries.” Additionally,
epoxypentane with ethyl carbamate (urethane). Reaction conditions
“naturally occurring biologically active. . .cyclic
b) aqueous boric acid (30 mol%) and 3(A)/5(B) drops of glycerol in
water at room temperature.**
amino alcohols, like quinines. . .are used in the
treatment
of
malaria.”23
Additionally, Carbamates are
receiving new attention in
medicinal chemistry for their
“application in drug design and
discovery.” Carbamates are
“chemical stability,” have a high
“capability to permeate cell
membranes,” and are used as
Figure 14. Method 11: Solvent free, cyanuric trichloride catalyzed aminolysis of 1,2“protecting groups for amines
epoxyoctane using ethyl carbamate.**
and amino acids in organic
synthesis and peptide
chemistry.” An epoxide aminolysis using carbamates as a weak nucleophile is a novel approach
to aminolysis with an aliphatic amine, since “carbamate functionality is related to amide-ester
hybrid features.”34,35
The EPA defines green chemistry as the “design of chemical products and processes that
reduce or eliminate the generation of hazardous substances.”36 In recent years, green chemistry
became popular as individuals have grown more environmentally conscious. As seen in methods
9ab and 11 respectively, the aqueous boric acid/glycerol catalyzed aminolysis and “Synthesis of
β-amino alcohols by ring opening of epoxides with amines catalyzed by cyanuric chloride under
mild and solvent-free conditions” provide procedures for step 2 which reduce the use of organic
solvents in an attempt to employ green chemistry.21,22
Despite the best intentions for an efficient, environmentally conscious combination of
steps 2 and 3 of the proposed synthetic plan, neither methods 9ab or 11 proved to be
successful. For methods 9ab, the product from method 8 was used to run a glycerol/boric acid
chelate acid catalyzed aminolysis of a terminal epoxide using ethyl carbamate as a weak
nucleophile.21 However, after running GCMS and NMR for the product from method 8, the
epoxidation procedure proved to be unsuccessful. Because of this, the epoxide starting for
methods 9ab was not present. Therefore, the reaction could not occur. The GCMS analysis for
Method 11 indicated the presence of both the starting reagents--1,2-epoxyoctane and ethyl
carbamate. This indicates that the reaction did not proceed.
11

As a key reaction in the synthesis of the
target molecule, a model reaction between
1,1-formaldoxime and 1,4-pentadiene resulted
in a simplified 3-bromoisoxazoline. The
procedure for this reaction was adapted from
16. Method 14: Model synthesis of a 3-bromoisoxazoline from
Pinto (2008). It is significant that our procedure Figure
1,4-pentadiene for step 5 of Phase 2.**
which limited 1,1-dibromoformaldoxime
resulted in a single 3-bromisoxazoline ring with a remaining double bond. This reaction proved
to be successful as confirmed through GCMS analysis.
Terminal Epoxide
Synthesis
Method
Reagents

Variations in Method

Product Description

GC-MS Analysis
NMR Analysis
Percent Yield

Method 7
Pentene, mChloroperbenzoic
acid, potassium
hydroxide
Porto (2005), 1 mmol
of pentene starting
material

Method 8
Pentene, mChloroperbenzoic
acid, potassium
hydroxide
Porto (2005), 10
mmol of pentene
starting material

Method 12
Pentene, mChloroperbenzoic
acid, potassium
hydroxide
Porto (2005), 1 mmol
of pentene starting
material, added
pressure
Clear colorless liquid

Method 13
Pentene, mChloroperbenzoic
acid, benzyltriethyl
amine chloride,
Biphasic,
Vishwakarma et al.
(1998), Davis and
Chattopadjyay (1987)
Orange/brown liquid

Small amount clear
colorless liquid, with
white precipitate

Yellow liquid

Dichloromethane
solvent peak at
1.470min

Dichloromethane
solvent peak at
1.470min

1,2-epoxypentane
present at 2.317 min

(A.18)
158.77% (1.37g)

N/A
------------------------

dichloromethane
(1.470min), 1,2epoxypentane
(2.316min)
N/A
54.5% (.176g)

N/A
-------------------------

Table 5. Summary of synthetic methods attempted in the synthesis of a terminal epoxide as a model for step 1 of phase 1 of the
proposed synthetic plan .**
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Aminolysis of Terminal
Epoxide
Method
Method 9a
Product mixture from method
Reagents
8, ethyl carbamate, boric acid,
glycerol
Halimehjani et al (2012),
Variations in Method catalyzed by boron chelate
complex, 3 drops of glycerol
Product Description
Clear colorless liquid
dichloromethane (1.470 min)
and ethyl acetate (2.323 min)
GC-MS Analysis

Method 9b
Product mixture from method
8, ethyl carbamate, boric acid,
glycerol
Halimehjani et al (2012),
catalyzed by boron chelate
complex, 5 drops of glycerol
Clear colorless liquid
dichloromethane (1.477 min)
and ethyl acetate (2.333 min)

Method 11
1,2-epoxyoctane, ethyl
carbamate, cyanuric
trichloride, hydrochloride
Kamble and Joshi (2009),
catalyzed by cyanuric
trichloride, solvent free
Clear colorless liquid
Starting reagent 1,2epoxyoctane (8.511 min,
library search quality of 80),
starting reagent urethane
ethyl carbamate (6.161 min,
library search quality of 87),
1,2-octanediol (10.987 min)

Table 6. Summary of synthetic methods attempted in the aminolysis of a terminal epoxide using carbamates as a model for the
combined steps 2 and 3 of phase 1 of the proposed synthetic plan.**

1,3-Cycloaddition Using 1,4-pentadiene
Method

Product Description

Method 14
1,4-pentadiene, dibromoformaldoxime, sodium
bicarbonate
Clear colorless liquid

GC-MS Analysis

3-bromoisoxazoline (9.613 min) in ethyl acetate (2.544
min)

Reagents

Table 7. Summary of the synthetic method attempted in the synthesis of a novel 3-bromoisoxazoline as a model for step 5 of
phase 2 of the proposed synthetic plan .**

Conclusions and Future Work
A novel 3-bromoisoxazoline has been proposed as a PfGAPDH inhibitor with potential
interactions in both the active site and the NAD+ binding site. A novel 3-bromoisoxazoline has
been synthesized and an epoxidation procedure has been modeled. While the proposed drug
and synthetic route have theoretical support, the cost of reagents, difficulty in storage and
potential decomposition of products, and large time investment of the synthesis limit its
usefulness. Future work could attempt the two phases of the synthetic plan as seen or attempt
to functionalize the 5-propenyl group on the simplified isoxazoline. More realistically, future
work could include the use of the remaining 1,1-dibromoformaldxoime to synthesize novel 3bromosoxazolines. These could be used in an investigation of potential ether groups in the 3postion on the isoxazoline ring.
Experimental Section
Method 1a: An aldoxime was attempted to be synthesized from isobutylformate with a
procedure adapted from Rodrigues (2013), using 25% of the suggested molar ratios. This
corresponds to Method 1a in table 2. First, a gas trap was set up to collect any gaseous HCl
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which could form. Then, 0.58mL of isobutylformate was dissolved in 12.5mL of methanol in a
50mL round bottom flask. 1.057g of NH2OH HCl was dissolved in 3mL of DI water, and was
added to the solution of isobutylformate in methanol. This was then stirred for 2.5 hours at
room temperature. After stirring, the reaction mixture was poured into a separatory funnel,
then extracted using 4mL of diethyl ether three times saving the top organic layer and pouring
the bottom aqueous layer back into the separatory funnel. After the first addition of diethyl
ether, a GCMS sample was taken. However, it was difficult to see the separation between the
organic layer and the aqueous layer, because of the fast evaporating solvent. Because of this,
the aqueous layer extracted was once more by adding using 13mL of diethyl ether. The
aqueous bottom layer was saved, and the organic top layer was dried with some anhydrous
sodium sulfate until the clumping looked like sand. A gravity filtration was completed by
wetting a piece of filter paper with diethyl ether in a funnel, the pouring over the organic layer
with anhydrous sodium sulfate, and finally rinsing both the filter paper and the organic
container with diethyl ether. This solution was stored for a week before being used in Method
1b.
Method 1b: The synthesis of an isoxazoline was attempted from the product of Method 1a as
discussed in Method 1b in table 3. The procedure was adapted from Rodrigues (2013). First the
organic solution from Method 1a was cooled to 14oC. Then at 15oC, 0.795mL of triethylamine
and 0.584g of cyanuric acid were carefully added with a spatula. A very small amount of
cyanuric acid caused the reaction to fizz, and after adding both the triethylamine and the
cyanuric acid the temperature of the reaction mixture rose to 24oC. The reaction mixture was
cooled in an ice bath for 15min reaching 7oC. Then the reaction was stirred for 34min, and the
white precipitate was removed through simple filtration. Then 0.940mL of methyl acrylate, the
dipolarophile, was added to the organic solution resulting from the filtration. This was stirred
for 4 hours and 11min. The reaction solution was stored and capped over the weekend. Then
precipitate was filtered out of the solution once again, because it may have been isocyanuric
acid as suggested by Rodriguez (2013). This precipitate was saved. The resulting organic
solution was rotovapped. The solution decreased in volume significantly and became a darker
yellow color. After storing the rotovapped solution for a week, some solid crystalized on the
side of the round bottom flask. At this point, another GCMS sample was taken and dissolved in
diethyl ether and ethanol.
Method 2a: An aldoxime was attempted to be synthesized from isobutylformate with a
procedure adapted from Rodrigues (2013), using 25% of the suggested molar ratios. This
corresponds to Method 2a in table 2. For method 2a, the same reaction from method 1a was
attempted; however, the solvent and some reaction times were adjusted--ethanol was used as
the solvent instead of methanol, the reaction solution was stirred for 2 hours at room
temperature, and the reaction solution was extracted with 20mL of dichloromethane and 10mL
of DI water instead of diethyl ether.
Method 2b: The synthesis of an isoxazoline was attempted from the product of Method 1a as
discussed in Method 2b in table 3. The procedure was adapted from Rodrigues (2013). For
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method 2b, the same reaction from method 1b was attempted; however, the solvent for the
reaction was dichloromethane.
Method 3: In both methods 3 and 5, the synthesis of glyoxylic acid aldoxime was attempted to
eventually be used as a starting reagent in the synthesis of 1,1-dibromoformaldoxime as seen in
table 3. The procedure was adapted from Ramòn (2010). The general procedure for both
methods--Monitor the reaction periodically using TLC with 5% Acetic Acid in Ethyl Acetate as
the solvent. Create a mixture of 1:1:2 H2O/EtOH/ice (20mL), then add 20 mmol of aldehyde
(1.841g of glyoxylic acid) and 1.39g (20mmol) of hydroxylamine hydrochloride. While keeping
the temperature below 30oC, add 4mL of a 50% aqueous solution of NaOH (40mmol). Stir for
18hr (time from 1p, may act most similarly to a close acid group). Extract with Et2O. While
keeping the temperature below 30oC, add concentrated HCl to the aqueous phase until the pH
reaches 6. Extract with Et2O again, then dry the organic phases over MgSO 4. Finally, evaporate
solvent.
A very careful attempt to produce a mixture of 1:1:2 H2O/EtOH/ice (20mL) proved to be
unsuccessful because of the ice melted quickly and the amount of ice added was difficult to
measure. In method 3, more ice was added than originally planned to keep the temperature
down when the aqueous solution of NaOH was added. First, 1.872g of glyoxylic acid
monohydrate and 1.404g of NH2OH HCl were added to the 1:1:2 H2O/EtOH/ice mixture. Then
1.605g of NaOH pellets were dissolved in water after adding the NH2OH HCl. Eventually added
0.846g more NaOH pellets dissolved in water later to make up for the base lost to the acid
group of glyoxylic acid. The NaOH solution was not allowed time to cool fully before adding it to
the reaction mixture. NaOH was added to the reaction solution too quickly, so the temperature
rose to 30oC. In an attempt to maintain the temperature, more ice was added. After adding the
NaOH solution, the reaction mixture was stirred for 44 hours. After stirring, the reaction
mixture was extracted with diethyl ether. The organic layer was saved, and then the aqueous
layer was brought to 6pH using concentrated HCl. Finally, the aqueous layer was extracted once
again with diethyl ether again, and two organic layers were combined. The combined organic
solution was gravity filtered through a bed of MgSO4. The resulting organic solution was
rotovapped with no heat which yielded 0.482g (26.9% yield) of product.
Method 4: For methods 4 and 6, the synthesis of 1,1-dibromoformaldoxime was attempted
from the resulting product from Method 3 as seen in table 4. The procedure was adapted from
Wang (2017) abstract. First an ice bath was created and 10mL of water was added to a round
bottom flask in the ice bath. Then another 10mL of water was added to the round bottom flask
containing 0.482 g of product from method 3, and then this solution was added to the round
bottom flask in the ice bath. After 15min the solution cooled to 2oC, and 0.56mL of liquid
bromine was added to the solution. This did not fully dissolve and collected at the bottom. This
mixture was stirred for 3hours and 1min and was then capped and stored in the fridge. A week
later, the reaction solution was retrieved from the fridge and solid had formed around the
magnetic stir bar. The reaction mixture was poured into a separatory funnel, and the round
bottom flask was rinsed with ethyl acetate. Three layers formed in the separatory funnel after
shaking—top organic was red and clear, middle aqueous was yellow and clear, and the bottom
15

layer was red bromine. The aqueous later was poured back into the separatory funnel and
extracted with 12mL of ethyl acetate and only two layers formed. The top organic layer was
saved with the organic from the first extraction. The aqueous layer was extracted with ethyl
acetate once again, forming two layers. This organic layer was saved separately from the rest of
the organic layers. The organic layers from the first two extractions was dried with Na2SO4,
filtered into a 100mL round bottom flask (mass=45.036g), and was rotovapped some then
stored in the fridge overnight. Then the rotovapping was continued resulting in 0.069g of
white/peachy product. A GCMS sample was taken with ethyl acetate as the solvent (A.8). The
organic layer from the final extraction was dried with Na2SO4 was dried with Na2SO4, filtered
into a 25mL round bottom flask (mass=28.338g), and was rotovapped resulting in a small streak
of yellow solid product, .005g of product. A GCMS sample was taken with ethyl acetate as the
solvent (A.7).
Method 5: In both methods 3 and 5, the synthesis of glyoxylic acid aldoxime was attempted to
eventually be used as a starting reagent in the synthesis of 1,1-dibromoformaldoxime as seen in
table 3. The procedure was adapted from Ramòn (2010) as discussed in Method 3. An aqueous
solution of 2.413g of NaOH in 6.1mL was prepared. 1.842g of glyoxylic acid monohydrate and
1.392g of NH2OH HCl were added to the 1:1:2 H2O/EtOH/ice mixture. Then the fully cooled
aqueous NaOH solution was added dropwise, never reaching 30oC. After adding NaOH, the
reaction mixture was stirred for 22 hours. After stirring, the reaction mixture was extracted
with diethyl ether. The organic layer was saved, and then the aqueous layer was brought to 6pH
using concentrated HCl. Finally, the aqueous layer was extracted once again with diethyl ether
again, and two organic layers were combined. A few spatulas of MgSO4 was added to dry the
resulting organic solution, and then the solution was gravity filtered. The resulting solution was
rotovapped without heat. This yielded 1.0565g (59.3% yield). A GMCS sample was taken (A.10).
Method 6: For methods 4 and 6, the synthesis of 1,1-dibromoformaldoxime was attempted
from the resulting product from Method 3 as seen in table 4. The procedure was adapted from
Wang (2017) abstract. 20mL of DI was added to the liquid product from method 5. This was
poured into a 50mL round bottom flask and placed in an ice bath. 1.3mL of liquid Br2 was added
to the solution and pooled at the bottom of the solution. The reaction mixture stirred for 3
hours and was then stored in the fridge. A few days later, the reaction solution was retrieved
from the fridge and no solid had formed. The reaction mixture was poured into a separatory
funnel, the round bottom flask was rinsed with 2.20mL of ethyl acetate, and then 10mL of ethyl
acetate were added to the separatory funnel—3 layers formed. Top organic was red and clear,
middle aqueous was orange and cloudy, and the bottom layer clear red. After shaking, 2 layers
formed, and after pouring out the top layer considered to be the organic, but there appeared to
be too much. Because of this a few drops of water were added to the bottom layer still in the
separatory funnel. The water sat on top of the solution. A few drops of water were added to
the poured off top layer, and the drops dissolved. Because of this, the poured off layer was
determined to be the aqueous. The aqueous layer was added back into the separatory funnel,
and the bottom red organic layer was drained out. An upper organic layer had formed and was
left in with the aqueous layer. This was then extracted with 10mL of ethyl acetate. Only two
layers formed this time. The drop test was performed once again, and bottom layer was found
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to be the aqueous layer. The top organic layer was saved separately from the previously saved
bottom red organic layer and the aqueous layer was extracted two more times with 10mL of
ethyl acetate each. The resulting organic solution from these two extractions were combined
with the top organic layer from the previous extraction. The combined top organic layers were
dried with Na2SO4 and filtered into a 24/40 200mL round bottom flask (mass=95.5492g) to
rotovap without heat in a room temperature water bath. The organic solvent did not fully
evaporate, and the resulting solution was stored in the fridge. The separately saved bottom red
organic layer was also dried with Na2SO4, filtered into a 200mL 24/40 round bottom flask
(mass=65.444g), and was stored in the fridge while waiting to rotovap. A GCMS sample was
taken from the product mixture (A.11).
Method 7: Model of step 1 from phase 1 of the proposed synthetic plan—synthesis of a
terminal epoxide from pentene using mCPBA as the epoxidizing agent. The reaction procedure
was adapted from Porto (2005).18 While in an ice bath, 0.10mL of pentene was added to 25.0mL
of dichloromethane in a 50mL 14/22 round bottom flask. The solution was cooled to 2.1oC, and
then 0.240g of mCPBA were added to the solution. This brought the temperature up to 5oC.
While still in the ice bath, the reaction solution was stirred for 25hours and 55min with a CaCl2
drying tube. A TLC of the reaction solution was taken 13min into the stirring time using a 1:4
mixture of ethyl acetate: hexane. At some point during the stirring time the magnetic stirrer
stopped stirring. At this point the white pieces of mCPBA appeared to be fully dissolved, and
some of the solvent had evaporated leaving a white ring of precipitate around half a centimeter
from the surface of the reaction solution. Still in the water bath and 23 hours into the stirring
time, the reaction was covered with parafilm and placed on a new magnetic stirrer. 0.6193g of
KOH pellets were dissolved in 6.1mL of DI water added to a 50mL Erlenmeyer flask. This
solution was cooled in an ice bath while setting up for the wash. A 125mL was rinsed with
125mL was rinsed with DI water and the reaction solution stopped stirring. the reaction
solution was washed with 5.0mL of the ice-cold KOH solution in the 125mL separatory funnel.
The organic layer was drained out into a 50mL Erlenmeyer flask and saved. Then the remaining
aqueous layer was extracted three times with 10.0mL of dichloromethane. The resulting
organic solution was combined with the organic solution from the wash in the 50mL
Erlenmeyer flask. This was dried with Na2SO 4, decanted into a 100mL 19/22 round bottom flask,
and then rotovapped in a water bath at 28oC. A very small amount of product remained and
was stored until a GCMS sample was taken. A few drops of dichloromethane were added to the
round bottom flask and then pipetted into the GCMS vial (A.16).
Method 8: Model of step 1 from phase 1 of the proposed synthetic plan—synthesis of a
terminal epoxide from pentene using mCPBA as the epoxidizing agent. This scaled up reaction
procedure was the same as method 7.18 Corresponding to table 5. First, an ice bath was created
and a 500mL 14/22 round bottom flask was placed inside of it. Then 1.10mL of pentene were
dissolved in 251.5mL of dichloromethane in the round bottom flask. The solution was cooled to
1oC and 2.042g of mCPBA were added to the solution. The reaction was stirred for 25hours and
45min. While the reaction was still stirring, 50.8mL of DI water was added to a 250mL
Erlenmeyer flask in an ice bath. Then 5.111g of KOH pellets were dissolved in the water. The
reaction stopped stirring, and the chilled 50.8mL solution of KOH and the reaction solution
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were added to a 500mL separatory funnel. This was shaken and the organic layer was drained
out and saved. The aqueous layer was added back into the separatory funnel and extracted
three times with 9.9mL, 10.0mL, and 15.1mL of dichloromethane respectively. The resulting
organic layers were combined, dried with Na2SO4, gravity filtered into a 500mL 14/22 round
bottom flask (mass=142.3445g). The solution was rotovapped, but a bubble of water formed at
the bottom of the round bottom flask. The solution was transferred into a 400mL beaker, a few
drops were spilled, and the solution was dried once again with Na2SO4, and filtered back into
the 500mL round bottom flask. This solution was rotovapped again and was then capped,
parafilmed, labeled, and saved. The yield was 1.3675g (158.77% yield). GCMS and NMR samples
were taken (A.17 and A.18 respectively).
Method 9a: Model of step 2 from phase 1 of the proposed synthetic plan—boric acid and
glycerol in water catalyzed opening of 1,2-epoxypentate using the product mixture from
method 8 and ethyl carbamate as seen in tables 5 and 6 respectively.35 The reaction procedure
was adapted from Halimehjani (2012).21 First a solution of 10mL of 30 mol% of aqueous boric
acid was attempted to be prepared through adding 14.453g of boric acid and 10mL of DI water
to a 50mL Erlenmeyer flask. This was stirred but not easily dissolved and set aside. Next, 0.25mL
of product from method 8 and 0.26mL of ethyl carbamate were added to a 14/22 50mL round
bottom flask. After a discussion with Ahlberg and a literature exploration into the solubility of
boric acid,37 a saturated solution of boric acid was prepared through adding 20-30mL at time of
water to the previously prepared boric acid in the Erlenmeyer flask, transferring to a larger
plastic storage container until 231.00mL of DI water had been added to the boric acid solution,
making a total of 241.00mL of saturated boric acid solution. After this, 3.1mL of saturated boric
acid solution and 2mL of DI water were added to the 50mL round bottom flask containing
product mixture from method 8 and carbamate. 3 drops of glycerol were added to the reaction
solution and stirring began. Alkacid test paper was used to test the pH of the at the beginning
of stirring the reaction—pH of 4 (orange color). Then the reaction mixture was covered with
parafilm and stirred for 14 hours and 22min. A separatory funnel was rinsed with DI water, then
10mL of ethyl acetate and the reaction solution were added to the separatory funnel. The
reaction mixture was extracted three times with 10mL of ethyl acetate. The resulting organic
mixture was left sitting in the hood and water droplets pooled together in the bottom of the
Erlenmeyer flask. Because of this, the organic solution was decanted into another flask and
dried with NaSO4, gravity filtered into a 100mL 19/22 round bottom flask, parafilmed, and
stored for two days. This solution was briefly rotovapped in a water bath at 72oC, then the
water temperature was lowered to 43oC, and rotovapping continued. The solvent did not fully
evaporate and a GCMS sample was taken (A.19).
Method 9b: Model of step 2 from phase 1 of the proposed synthetic plan—boric acid and
glycerol in water catalyzed opening of 1,2-epoxypentate using the product mixture from
method 8 and ethyl carbamate as seen in tables 5 and 6 respectively.35 The reaction procedure
was adapted from Halimehjani (2012).21 The same saturated boric acid solution which was
prepared for method 9a was used for method 9b. First, 0.26mL of product from method 8 and
0.26mL of ethyl carbamate were added to a 14/22 25mL round bottom flask. After this, 3.1mL
of saturated boric acid solution and 2mL of DI water were added to the 25mL round bottom
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flask containing product mixture from method 8 and carbamate. 5 drops of glycerol were added
to the reaction solution and stirring began. Alkacid test paper was used to test the pH of the at
the beginning of stirring the reaction—pH of 6 (brown color). Then the reaction mixture was
covered with parafilm and stirred for 14 hours and 22min. A separatory funnel was rinsed with
DI water, then 10mL of ethyl acetate and the reaction solution were added to the separatory
funnel. The reaction mixture was extracted three times with 10mL of ethyl acetate and the
resulting organic solution was dried with NaSO4, gravity filtered into a 100mL 19/22 round
bottom flask, parafilmed, and stored for two days. After this, the organic solution was
rotovapped in a water bath at 35oC, increased the temperature to 40oC, and finally at 45oC. The
solvent did not fully evaporate. A GCMS sample was taken (A.20).
Method 11: Model of step 2 from phase 1 of the proposed synthetic plan—solvent free,
cyanuric trichloride catalyzed aminolysis of a terminal epoxide corresponding to table 6.
Procedure adapted from Kamble (2010).22 As suggested by Dr. Hayes, a 200% molar excess of
1,2-epoxyoctane was used. First, 0.46mL of 1,2-epoxy octane was added to a 20mL round
bottom flask. Then 0.8mL of ethyl carbamate and .11g of cyanuric trichloride were dissolved in
the 1,2-epoxyoctane. The reaction was stirred for 4 hours and 28min. TLC of ethyl carbamate,
1,2-epoxyoctane, and reaction solution were taken 42 min into the stir time and another TLC
was taken near the end of the stir time. A 50/50 mixture of ethyl acetate and petroleum ether
was used as the mobile phase. While the mixture was still stirring, 1mL of concentrated HCl
solution was added to an empty 100mL beaker, and then 23mL of DI water were added to the
HCl to produce 24mL of 0.5N HCl solution. 10mL of the 0.5N HCl solution was added to a
separatory funnel. The reaction solution stopped stirring and was added to the separatory
funnel. The round bottom flask was rinsed with 5mL of .5mL and added this to the separatory
funnel. The excess aqueous HCl was disposed of in the aqueous waste container. The
separatory funnel was shaken, and the both the aqueous and organic layers were left in. Then
the mixture in the separatory funnel was extracted three times with 10mL of diethyl ether each.
The resulting organic solution was dried with NaSO4 and then gravity filtered into a round
bottom flask. The dried solution was then rotovapped and a sample was taken for GCMS
analysis.
Method 12: Model of step 1 from phase 1 of the proposed synthetic plan--Epoxidation of
pentene under pressure corresponding to table 6. Procedure adapted from Porto (2005) with
the addition of pressure as suggested by Ahlberg and influenced by Sheng (1970).18,19 First a
pressure flask was placed in a ices bath. A pipet was used to collect 8.0mL of dichloromethane
from a bottle, but then something was floating in the graduated cylinder. Because of this the
dichloromethane was gravity filtered into the pressure flask to give a clear liquid. Then 0.110mL
of pentene were added to the pressure flask, and another 8.2mL of dichloromethane were
added to the pressure flask through the gravity filter. This solution was then cooled to 3oC, and
266g of mCPBA were added to the pressure flask. The cap of the pressure flask was screwed on
and the reaction stirred for 23 hours and 36min. Then the closed pressure flask was stored in
the fridge overnight. The next day an aqueous solution of 0.577g of KOH pellets and 10mL of DI
water was prepared in a 25mL Erlenmeyer flask. The reaction solution was retrieved from the
fridge, and the 10mL KOH solution was added to a separatory funnel. Then the stored reaction
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solution was added to the separatory funnel and shaken. Then both the aqueous and organic
layers were removed, and the organic layer was saved. The top aqueous layer was added back
into the separatory funnel and then extracted with dichloromethane. Finally, the two organic
layers were combined, dried with Na2SO 4, gravity filtered into storage containers, and a GCMS
sample was taken (A.22).
Method 13: Model of step 1 from phase 1 of the proposed synthetic plan—epoxidation of a
terminal alkene. Biphasic epoxidation of pentene procedure adapted from Vishwakarma (1998)
and Davis and Chattopadhyay (1987).32,33 This corresponds to table 6. First 0.097g of benzyl
triethylamine chloride (BTEAC), a phase transfer agent, was added to a 50mL Erlenmeyer flask
labeled BTEAC and then dissolved in 2.7mL of dichloromethane. Then 0.410mL of pentane were
added to the BTEAC solution. Next 4.1mL of saturated NaHCO 3 solution were added to a 25mL
round bottom flask in an ice bath. The BTEAC and pentene solution was poured into the 25mL
round bottom flask. In a separate Erlenmeyer flask, 0.895g of mCPBA was dissolved in 7.5mL of
dichloromethane. When the reaction solution in the 25mL round bottom flask reached 5oC,
mCPBA in dichloromethane solution was added dropwise while stirring the solution. 5-10 drops
were added at a time and 5 seconds of stirring was allowed in between adding mCPBA solution.
During this time, the pipet rested in and was fully emptied back into the mCPBA solution
because early on the mCPBA quickly recrystallized when exposed to air and blocked the end of
the pipet. After adding all of the mCPBA solution the reaction temperature was 4oC, and the
reaction mixture was stirred for another hour. The reaction solution was placed in the fridge. A
month later, a 10% solution of Na2SO 3 was prepared by dissolving 0.49g of Na2SO 3 in 4.9mL of
DI water in a beaker. The stored reaction solution was retrieved from the fridge and was lightly
shaken to dissolve precipitate. 4.5mL of cold DI water was added to a separatory funnel and
then the reaction solution was added to the separatory funnel then shaken. Drop test was
performed to confirm that the bottom layer was organic. The both the aqueous layer and the
organic layer were drained out. Next the resulting organic solution and the prepared 10%
solution of Na2SO3 were added to the separatory funnel and shaken, and both layers were
drained out. Next 2mL of saturated aqueous NaCL solution was added to the separatory funnel
and the organic solution was poured back in. This was shaken, and then the organic bottom
layer was drained out. After this, 0.087g of calcium carbonate were added to the organic
solution as a drying agent; however, this was incorrect and quickly gravity filtered out. After this
0.559g of potassium carbonate were added to the reaction solution and allowed to sit for 2
hours. Then the organic solution was gravity filtered into a 25.446g 19/22 25mL round bottom
flask and was rotovapped at 37oC to a small amount of liquid. The yield of the reaction was
0.176g (54.5% yield). A GCMS sample was taken and the rest stored in the freezer (A.23).
Method 14: Model of step 5 from phase 2 of the proposed synthetic plan--1,3- dipolar
cycloaddition using 1,4-pentadiene as a dipolarophile and 1,1-dibromoformaldoxime as a dipole
corresponding to table 7. Procedure was adapted from Pinto (2008).26 First 66.8mL of ethyl
acetate was added to an empty 250mL 19/22 round bottom flask. Then 1g (the full vial) of 1,4pentadiene was added to the flask. The glass vial which contained the 1,4-pentadiene was
rinsed with ethyl acetate in an attempt to collect a GCMS sample (A.24) which later resulted in
mostly noise. 3.38g of 1,1-dibromoformaldoxime was added to the reaction solution in the
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round bottom flask. This dissolved quickly, and then 6.4g of NaHCO 3 was added to the solution.
This did not dissolve. The reaction was stirred for 1 hour and 50min and then the stirring speed
was increased to allow for more movement of the NaHCO3. At 2 hours and 30min into the
reaction, a TLC of the reaction solution was taken on 60 F2541 silica gel plate, using 95%
petroleum ether/5% ethyl acetate as the solvent. After stirring overnight, 22.5mL of DI water
was added to a 125mL separatory funnel, then the reaction solution stopped stirring and was
added to the separatory funnel. The solution was shaken and extracted. The resulting organic
solution was dried with a few scoops of Na2SO4. Then the organic solution was filtered into a
250mL 19/22 round bottom flask (mass of 93.094g) resulting in a clear colorless liquid. A GCMS
sample was taken for analysis (A25). The organic solution was stored in the freezer.
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GCMS Programs
D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M
Oven program: 30oC for 3min, then increase 15oC/min to 80oC for 0.1min, and then 10oC/min to
280oC for 0 min.
Acquisition mode: Scan
Temperature of Front SS Inlet H2: 250oC
Front SS Inlet H2 total flow: 33.6mL/min
Front SS Inlet H2 pressure: 1.1048psi
Front SS H2 split ratio: 50:1
Column #1 gas flow: 0.6mL/min
Column #1 pressure: 1.1048 psi
D:\PeytonsResearch\RESEARCHMETHOD1_1.M
Oven program: 30oC for 3min, then increase by 20oC/min to 80oC for 0.1min, and then
15oC/min to 280oC for 0 min.
Acquisition mode: Scan
Temperature of Front SS Inlet H2: 250oC
Front SS Inlet H2 total flow: 33.6mL/min
Front SS Inlet H2 pressure:1.1048psi
Front SS H2 split ratio: 50:1
Column #1 gas flow: 0.6mL/min
Column #1 pressure: 1.1048 psi
D:\PeytonsResearch\RESEARCHMETHOD1_2.M
Oven program: 30oC for 3min, then increase by 20oC/min to 80oC for 0.1min, and then
15oC/min to 280oC for 0 min.
Acquisition mode: Scan
Temperature of Front SS Inlet H2: 250oC
Front SS Inlet H2 total flow: 33.6mL/min
Front SS Inlet H2 pressure:1.1048psi
Front SS H2 split ratio: 50:1
Column #1 gas flow: 0.6mL/min
Column #1 pressure: 1.1048 psi

D:\Research_Sara_Josselyn \RESEARCHMETHOD2.M
Oven program: 30oC for 3min, then increase by 15oC/min to 200oC for 0.1min, and then
15oC/min to 300oC for 10 min.
Acquisition mode: Scan
Temperature of Front SS Inlet H2: 300oC
Front SS Inlet H2 total flow: 33.6mL/min
Front SS Inlet H2 pressure:1.1048psi
Front SS H2 split ratio: 50:1
Column #1 gas flow: 0.6mL/min
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Column #1 pressure: 1.1048 psi

D:\Sarajoshhighbpmethod\HIGHBOILINGSOLV_SJ2.M
Oven program: 28oC for 3.5min, then increase by 35oC/min to 300oC for 3min.
Acquisition mode: Scan
Temperature of Front SS Inlet H2: 200oC
Front SS Inlet H2 total flow: 33.6mL/min
Front SS Inlet H2 pressure: 1.0171 psi
Front SS H2 split ratio: 50:1
Column #1 gas flow: 0.6mL/min
Column #1 pressure: 1.0171 psi

Appendix

A.1 GC-MS analysis of isobutylformate (3.615 min) starting reagent in diethyl ether (1.313 min).
Using the MS data, the library search report of the NIST11.L database identified isobutyl
formate with a quality of 74 and diethyl ether with a quality of 46.
Method: D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M

A.2 GC-MS analysis of product mixture in methanol and diethyl ether for attempted synthesis of
aldoxime from isobutyl formate using Method 1a. Presence of isobutyl formate starting
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material at 3.451 min peak. Diethyl ether solvent peak at 1.330 min. Using the MS data, the
library search report of the NIST11.L database identified isobutyl formate with a quality of 43.
Method: D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M

A.3 GC-MS analysis of product mixture from Method 1b in diethyl ether. This is the product
from the attempted synthesis of isoxazoline from product mixture from Method 1a and methyl
acrylate using Method 1b. Presence of methyl acrylate starting material at 2.267 min peak.
Using the MS data, the library search report of the NIST11.L database identified methyl acrylate
with a quality of 91. Additionally, the library search report indicates the halogenation of the
methyl acrylate double bond to propanoic acid, 3-chloro-, methyl ester at the 5.962 min peak.
Method: D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M

A.4 GC-MS analysis of product mixture in ethanol, dichloromethane, and diethyl ether for
attempted synthesis of aldoxime from isobutyl formate using Method 2a. Presence of isobutyl
formate starting material at 3.444 min peak. Ethanol, diethyl ether, and dichloromethane
solvent peaks at 1.254 min, 1.327 min, and 1.494 min, respectively. Using the MS data, the
library search report of the NIST11.L database identified isobutyl formate with a quality of 59.
Method: D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M
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A.5 GC-MS analysis of product mixture from Method 2b in ethanol, dichloromethane, and
diethyl ether. This is the product from the attempted synthesis of isoxazoline from product
mixture from Method 1a and methyl acrylate using Method 1b.
Method: D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M

A.6 GC-MS analysis of product mixture from Method 3 in diethyl ether, synthesis of glyoxylic
acid aldoxime.
Method: D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M

A.7 GC-MS analysis of yellow solution of product mixture from Method 4 in ethyl acetate
synthesis of dibromoformaldoxime. Ethyl acetate peak is present at 2.198 min. Using the MS
data, the library search report of the NIST11.L database identified the ethyl acetate solvent with
a quality of 49.

28

Method: D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M

A.8 GC-MS analysis of red solution of product mixture from Method 4 in ethyl acetate, synthesis
of dibromoformaldoxime. Ethyl acetate peak is present at 2.216 min. Using the MS data, the
library search report of the NIST11.L database identified the ethyl solvent with a quality of 80.
Method: D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M
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A.9 IR of glyoxylic acid starting material.
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A.10 GC-MS analysis of product mixture from Method 5 in diethyl ether, synthesis of glyoxylic
acid aldoxime. Peak at 1.303 min represents 99.99 percent of the solution listed as Propanoic
acid in the library search with a quality of 46.
Method: D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M

A.11 GC-MS analysis of product mixture from Method 6 in ethyl acetate, synthesis of
dibromoformaldoxime. Ethyl acetate peak is present at 2.267 min. Using the MS data, the
library search report of the NIST11.L database identified the ethyl solvent with a quality of 80.
Method: D:\alkenesfromalf2018\STANDARD_MIXED.D\final2018.M
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A.12 GC-MS analysis of pentene (1.418 min peak) starting reagent in dichloromethane (1.470
min).
D:\PeytonsResearch\RESEARCHMETHOD1_1.M
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33

34

A.13 NMR analysis of starting reagent of pentene in chloroform-D.
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A.14 IR of pentene starting material.
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A.15 NMR of ethyl carbamate starting material.
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A.16 GCMS analysis of product mixture from Method 7. Method 7 dichloromethane peak at
1.470min, product potentially at 2.319min.
D:\PeytonsResearch\RESEARCHMETHOD1_1.M
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A.17 Method 8 Product in dichloromethane 1.470min look closely at around 1.4—small peak
similar placement to pentene in dichloromethane. 2.30min could be product.
D:\PeytonsResearch\RESEARCHMETHOD1_1.M
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A.18 NMR analysis of Method 8 Product.
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A.19 GCMS Analysis of product from method 9A in dichloromethane (1.470 min) and ethyl
acetate (2.323 min, identified by library search report with a quality of 36).
D:\PeytonsResearch\RESEARCHMETHOD1_1.M

A.20 GCMS analysis of product 9B in dichloromethane (1.477 min, identified by library search
report with a quality of 47) and ethyl acetate (2.333 min, identified by library search report with
a quality of 36)
D:\PeytonsResearch\RESEARCHMETHOD1_1.M
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A.21 GCMS analysis of product from method 11, no solvent starting reagent 1,2-epoxyoctane
(8.511 min, library search quality of 80), starting reagent urethane or ethyl carbamate (6.161
min, library search quality of 87), 1,2-octanediol (10.987 min).
D:\Research_Sara_Josselyn \RESEARCHMETHOD2.M
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A.22 zoomed in GCMS analysis of Method 12 product in dichloromethane. 1,2-epoxypentane
present at 2.317 min.
D:\Research_Sara_Josselyn \RESEARCHMETHOD2.M
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A.23 Product from Method 13 in dichloromethane (1.470 min, quality of 43), 1,2-epoxypentane
(2.316 min) Pubchem MW 86.13 with fragments at 27, 41, 71 agrees with data at 2.31 min.
D:\Sarajoshhighbpmethod\HIGHBOILINGSOLV_SJ2.M
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A.24 GCMS Analysis of starting reagent 1,4-pentadiene in diethyl ether.
D:\PeytonsResearch\RESEARCHMETHOD1_2.M
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A.25 GCMS analysis of product from Method 14 (9.613 min) in ethyl acetate (2.544 min, quality
of 64). MW of simplified isoxazoline 3-bromo-4,5-dihydro-5-prop-2-enylisoxazoline=190.04
g/mol.
• 190.9—2 peaks Bromine isotopes present with a 1:1 ratio/splitting pattern Br79, Br81
• 149.9—2 peaks, loss of propenyl group—bromine still present
D:\PeytonsResearch\RESEARCHMETHOD1_2.M
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